With Interchangeability Nod, Viatris' Semglee Loses Its Identity

Now approved as an interchangeable biosimilar, US labeling for Viatris’ insulin aspart mirrors that of Sanofi’s Lantus and has shed data from two studies in type 1 and 2 diabetics that showed noninferiority to Sanofi’s Lantus; Viatris appears in line for one year of exclusivity.

The US FDA's first-ever interchangeable designation opens new roads for biosimilars. • Source: Nielsen Hobbs

Viatris Inc.’s Semglee (insulin glargine-yfgn) became the first biosimilar insulin – and the first interchangeable biologic product – in the US with the Food and Drug Administration’s 28 July approval, but lost its labeling on product-specific clinical efficacy and safety data in the process.

The FDA approved Semglee to improve glycemic control in adults and pediatric patients with type 1 diabetes and in adults with type 2 diabetes. It is the first interchangeable product...

The interchangeability designation means Semglee can be substituted at the pharmacy level, without physician intervention, for the reference product, Sanofi’s Lantus (insulin glargine). Such ease of substitution has long...

More from Biosimilars

More from Biosimilars & Generics